Soligenix
SNGXPhase 3Soligenix operates through two core business segments: a Specialized BioTherapeutics division developing treatments for rare diseases, and a Public Health Solutions division focused on medical countermeasures against biological and chemical threats. The company's lead candidate, HyBryte™ (SGX301), has demonstrated positive Phase 3 results for cutaneous T-cell lymphoma and is positioned as a potential first-in-class photodynamic therapy. With a diversified pipeline spanning oncology, infectious diseases, and biodefense, Soligenix leverages government grants and strategic collaborations to advance its development programs while managing financial resources carefully.
SNGX · Stock Price
Historical price data
AI Company Overview
Soligenix operates through two core business segments: a Specialized BioTherapeutics division developing treatments for rare diseases, and a Public Health Solutions division focused on medical countermeasures against biological and chemical threats. The company's lead candidate, HyBryte™ (SGX301), has demonstrated positive Phase 3 results for cutaneous T-cell lymphoma and is positioned as a potential first-in-class photodynamic therapy. With a diversified pipeline spanning oncology, infectious diseases, and biodefense, Soligenix leverages government grants and strategic collaborations to advance its development programs while managing financial resources carefully.
Technology Platform
Proprietary platforms include Synthetic Hypericin Photodynamic Therapy (SGX301) for oncology, a Thermostabilization Technology for vaccines, and an Oral Innate Defense Regulator (SGX942) platform for modulating inflammatory responses.
Pipeline Snapshot
1212 drugs in pipeline, 4 in Phase 3
| Drug | Indication | Stage |
|---|---|---|
| SGX942 + Placebo | Squamous Cell Carcinoma of the Oral Cavity and Oropharynx | Phase 3 |
| Hypericin + Placebo | CTCL/ Mycosis Fungoides | Phase 3 |
| SGX301 (synthetic hypericin) + Placebo | Cutaneous T-Cell Lymphoma | Phase 3 |
| oral beclomethasone 17,21-dipropionate + Placebo | Acute Gastrointestinal Graft vs Host Disease | Phase 3 |
| Hypericin + Placebo | Psoriasis | Phase 2 |
Funding History
3Total raised: $32M
Opportunities
Risk Factors
Competitive Landscape
In CTCL, HyBryte™ competes with UV-based phototherapies and topical chemotherapies, differentiating itself with a visible light mechanism that avoids DNA damage and carcinogenic risk. In biodefense, it competes for government contracts with other biotech firms, leveraging its validated thermostabilization platform as a key differentiator for vaccine development.
Company Info
Trading
Contact
Therapeutic Areas
Sectors
Partners
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile